Autism-friendly 'Guys and Dolls' at Saratoga Civic Theatre

Live theater is something many people find enjoyable and stimulating, but for those with sensory defects it can be uncomfortable and even painful.

Now South Bay Musical Theatre is offering an autism-friendly performance during its upcoming run of Guys and Dolls.

The performance takes place on May 31 at 7:30 p.m. and marks the first effort of a Bay Area theater company to offer an autism-friendly show.

In October 2011, Disney Theatrical Productions worked with the nonprofit Theatre Development Fund to stage an autism-friendly performance of The Lion King on Broadway in New York. It was so successful it is doing a second staging of the show in September; at the end of April it did a performance of Mary Poppins.

The SBMT production is at the urging of Anita Hsiung Carey, a vocal director and pianist with the theater company.

Carey's 8-year-old son has severe autism, but enjoys attending rehearsals with his mother.

Knowing how much he enjoys the rehearsals made Carey suggest the company try doing the special performance.

During the May 31 performance, house lights will be brighter, there will be no strobe lights, the sound will be lowered and audience members will be able to walk around the theater and talk during the show. Extra staff will be on hand to help.

Tickets for the special performance are $20 for adults and $10 for children. SBMT is donating proceeds from that show to Wings Learning Center, which

Regular performances of Guys and Dolls run May 19 to June 9 at Saratoga Civic Theatre, 13777 Fruitvale Ave., Saratoga. For information and tickets to any of the performances visit http://www.southbaymt.com or call 408.266.4724.

Read the original here:
Autism-friendly 'Guys and Dolls' at Saratoga Civic Theatre

Autism-friendly ‘Guys and Dolls’ at Saratoga Civic Theatre

Live theater is something many people find enjoyable and stimulating, but for those with sensory defects it can be uncomfortable and even painful.

Now South Bay Musical Theatre is offering an autism-friendly performance during its upcoming run of Guys and Dolls.

The performance takes place on May 31 at 7:30 p.m. and marks the first effort of a Bay Area theater company to offer an autism-friendly show.

In October 2011, Disney Theatrical Productions worked with the nonprofit Theatre Development Fund to stage an autism-friendly performance of The Lion King on Broadway in New York. It was so successful it is doing a second staging of the show in September; at the end of April it did a performance of Mary Poppins.

The SBMT production is at the urging of Anita Hsiung Carey, a vocal director and pianist with the theater company.

Carey's 8-year-old son has severe autism, but enjoys attending rehearsals with his mother.

Knowing how much he enjoys the rehearsals made Carey suggest the company try doing the special performance.

During the May 31 performance, house lights will be brighter, there will be no strobe lights, the sound will be lowered and audience members will be able to walk around the theater and talk during the show. Extra staff will be on hand to help.

Tickets for the special performance are $20 for adults and $10 for children. SBMT is donating proceeds from that show to Wings Learning Center, which

Regular performances of Guys and Dolls run May 19 to June 9 at Saratoga Civic Theatre, 13777 Fruitvale Ave., Saratoga. For information and tickets to any of the performances visit http://www.southbaymt.com or call 408.266.4724.

Read the original here:
Autism-friendly 'Guys and Dolls' at Saratoga Civic Theatre

Utah autism treatment pilot struggles for funding

Health Legislator is confident of funding, but expected donations from UHC, Zions are elusive.

Despite assurances during the Legislative session that major insurance companies and a bank would donate $1 million toward a new autism treatment pilot, the state has not yet received any money.

That could halve one part of the program, set to begin this summer, at a time when a study of a small area in Utah indicated the state could have the highest autism rate in the nation.

"As of right now there is no money," said Marc Babitz, director of the Division of Family Health and Preparedness at the Utah Department of Health. "I am not aware of one private donation."

But Rep. Ronda Menlove, R-Garland, who sponsored the bill to create the pilot, says there is "no question" that money is on its way.

"Weve been working with the entities this past week working out the details," she said.

Expected donor Zions Bank did not immediately comment. Intermountain Healthcare says it plans to provide financial support although the details are still being finalized.

The two-year pilot program is expected to pay for therapy for about 350 children between the ages of 2 and 6, through a combination of Medicaid, state and private dollars.

Three groups of children will be served, including up to 50 covered by the Public Employees Benefit and Insurance Program; at least 200 kids covered by Medicaid, supported by $4.5 million in Medicaid dollars; and up to 100 from the autism fund, paid in part with private dollars. Those children may be on private insurance or be uninsured.

Babitz said he remained hopeful the private money would still materialize; $1 million in state dollars will become available in July.

Read the original here:
Utah autism treatment pilot struggles for funding

Local students with autism write book

COLUMBUS, GA -

Recent studies show 1 in 88 children are diagnosed with autism in the United States.

A group of Columbus students are not letting their diagnosis hold them down, andthey can now say they are authors after penning the pages of a new book.

The short stories and pictures of animals inA is for Autismwereall written and illustrated by students with autism, like 16-year-old Keveran McDonald. Keveran's father, Mark, says it is overwhelming to see the pages A is for Autism.

"I'm very proud of his accomplishments. Sometimes you don't think things like this would be possible, but they surprise you. Just makes me really proud," said McDonald.

Rebecca Gristina, the President of the Board of Directors at Bridges Learning Center in Columbus, a school that focuses on helping autistic children, says this three-year project allowed a group of their students to channel their emotions.

"A lot of the kids struggle with building relationships and friendships with peers. Traditionally developing peers, and these stories are mostly about friendship," said Gristina.

All of the proceeds from book sales will go back to the school where 75% of the students have some kind of financial aid. That money will go to close that gap as well as help with therapy for the students.

"We involve our students in hypo-therapy which is horseback riding and water therapy. We also have a computer program called brain jog which focuses the kids on their eye movement in order to build that eye contact," said Gristina

McDonald says because of this school, his son has a chance to thrive.

Here is the original post:
Local students with autism write book

Columbus students with autism write book

COLUMBUS, GA -

Recent studies show 1 in 88 children are diagnosed with autism in the United States.

A group of Columbus students are not letting their diagnosis hold them down, andthey can now say they are authors after penning the pages of a new book.

The short stories and pictures of animals inA is for Autismwereall written and illustrated by students with autism, like 16-year-old Keveran McDonald. Keveran's father, Mark, says it is overwhelming to see the pages A is for Autism.

"I'm very proud of his accomplishments. Sometimes you don't think things like this would be possible, but they surprise you. Just makes me really proud," said McDonald.

Rebecca Gristina, the President of the Board of Directors at Bridges Learning Center in Columbus, a school that focuses on helping autistic children, says this three-year project allowed a group of their students to channel their emotions.

"A lot of the kids struggle with building relationships and friendships with peers. Traditionally developing peers, and these stories are mostly about friendship," said Gristina.

All of the proceeds from book sales will go back to the school where 75% of the students have some kind of financial aid. That money will go to close that gap as well as help with therapy for the students.

"We involve our students in hypo-therapy which is horseback riding and water therapy. We also have a computer program called brain jog which focuses the kids on their eye movement in order to build that eye contact," said Gristina

McDonald says because of this school, his son has a chance to thrive.

See the original post:
Columbus students with autism write book

Can Kinect Help Detect Autism?

At the University of Minnesotas Institute of Child Development in Minneapolis, Microsoft's Kinect is being put to a novel use: detecting autism. New Scientist reports that researchers have equipped a nursery with five Kinect cameras, which, together with computer vision algorithms that can detect unusual behavior, may be able to speed the diagnosis of autism.

How exactly does the system work? The Kinects can ID individual children based on their shape and clothing. Monitoring these children, the Kinects feed their data to a series of PCs with software that can track the kids activity levels, comparing them against an average. If a given child is either more or less active than average, he or she might have autism. Then again, he or she might just be tired, or hyper, which is why at that point an old-fashioned human doctor will have to weigh in on the matter.

"The idea is not that we are going to replace the diagnosis, but we are going to bring diagnosis to everybody," one of the researchers, Guillermo Sapiro, told New Scientist. "The same way a good teacher flags a problem child, the system will do automatic flagging and say, 'Hey, this kid needs to see an expert'."

This is one of the extreme instances of what Microsoft has termed the Kinect Effect, the tendency of people outside of Redmond to come up with novel uses for a technology originally intended simply for gaming. (It was an effect documented well before Microsoft decided to condone and, smartly, co-opt it.) Sapiro and colleagues will present their system at the forthcoming IEEE International Conference on Robotics and Automation in St. Paul.

Sapiro et al. hope to bring their novel use of the Kinect even further, perhaps automating some of what Sapiro calls the very difficult and expert analysis that a psychiatrist would do. Sapiros team has already developed computer-vision algorithms that can detect more subtle indicators of autism spectrum disorders, like a childs ability to follow an object with his eyes. Perhaps some day, a Kinect-powered video game could both entertain a child while testing him for a disorder.

New Scientist doesnt make clear whether Sapiros projects have official Microsoft approval, but Microsoft has endorsed at least one other project in which Kinect is used to treat children with autism, as evidenced by this video from last year.

BBDO and Autism Speaks also used Kinect for a bit of autism-related advocacy. In an effort to raise awareness about the challenges of parenting a child with autism, BBDO built an interactive Kinect-powered installation featuring a virtual girl who simply refused to look users in the eye.

Im unsure whether the proliferation of autism-related Kinect hacks says something profound about the nature of motion-sensing its connection to autism spectrum disorders, or whether its simply an indication of the ways in which Kinect hacks increasingly touch on every aspect of modern life. After all, autism certainly isnt the only medical condition people have tried to ameliorate, detect, or treat with Microsofts transformative technology.

Read more:
Can Kinect Help Detect Autism?

Officer urges autism training for first responders

By Alan Johnson

The Columbus Dispatch Friday May 11, 2012 5:49 AM

Sgt. Mark Farrar of the Akron Police Department, here with his son Kyle, spends many days speaking to fellow law-enforcement officers about how to deal with people with autism, like Kyle, now 5.

Akron Police Sgt. Mark Farrar knows the facts of autism in his head and the pain of autism in his heart.

With the incidence of autism rising rapidly 1 in 88 children (and 1 in 54 boys) are born with some form of it law-enforcement agencies are being affected because, Farrar says, the autistic are seven times as likely as others to come into contact with first responders such as police, fire and paramedics. They also are more likely to be crime victims.

We talk about autism in kids as if they mysteriously disappear when they become adults, Farrar said yesterday at Attorney General Mike DeWines Two Days in May crime-victims conference in the Hyatt Regency. Those kids are growing up, becoming adults, living in our communities. We cant assume first responders know how to deal with them on their own.

Farrar, 39, who spends half his time patrolling the streets of Akron, has a son Kyle, 5, who has Aspergers syndrome, a high-functioning form of autism. Farrar became a self-taught expert on the subject after his sons autism was diagnosed, and he now trains law-enforcement and other organizations about autism, often on his own time.

Autism is a development disorder that often shows up early in childhood. It is marked by communication and behavioral issues but is not mental retardation.

An audience of 1,000 was spellbound yesterday as Farrar blended the story of his familys struggles raising Kyle and the growing trend for autistic individuals to become victims and sometimes perpetrators of crime. He showed a clip from the Tom Cruise and Dustin Hoffman movie Rain Man, offering a glimpse of life with autism.

We have to convince police theres a need for this training, not because I have a son, but because of research and statistics, he said. As I say in training law enforcement, This is coming to a call near you.

See more here:
Officer urges autism training for first responders

Autism Speaks Selects Prometheus Research to Develop Integrated Data Management System

NEW HAVEN, Conn., May 10, 2012 /PRNewswire/ -- Prometheus Research, a leading provider of data management services for behavioral and biomedical research, announced today that it has been selected by Autism Speaks to develop an integrated data management system which will enable autism researchers to securely manage and share their data.The newly organized Autism Genetic Resource Exchange (AGRE) Data Coordinating Center (DCC) centralizes clinical, environmental, and biospecimen data from several Autism Speaks-funded programs and initiatives to better serve the research community.

Using their Research Exchange Database (RexDB) platform and best-of-breed electronic data capture system, ROADS, Prometheus empowers researchers to effectively manage and exchange interdisciplinary data while maintaining the flexibility to incorporate new significant results such as genetic, EEG, imaging data and additional studies.

"We're very excited to begin working with Autism Speaks, a premier autism research and advocacy organization.This project will enable wider integration of Autism Speaks' valuable research data and enable them to re-use the data in ways not possible before," said Dr. Leon Rozenblit, President and CEO of Prometheus Research.

Prometheus Research's domain expertise in autism and related disorders makes it an ideal partner for Autism Speaks.Prometheus has supported or collaborated on some of the largest and most ambitious autism research endeavors in the world, including the National Database for Autism Research (NDAR). The tools and processes they've helped develop in the areas of study governance, data collection, data curation, data distribution, and data persistence are now considered best practices for collaborative research, and are already in use at places like the Yale Child Study Center and the Marcus Autism Center.

"AGRE's dedication to collaboration and data sharing has accelerated the pace of autism research significantly over the last decade," said Autism Speaks Vice President of Clinical Programs Clara Lajonchere, Ph.D. "We strive to utilize technology that will meet the emerging needs of science and feel that the team at Prometheus Research has developed the tools that will help us achieve our goals."

About Autism SpeaksAutism Speaks is the world's leading autism science and advocacy organization. It is dedicated to funding research into the causes, prevention, treatments and a cure for autism; increasing awareness of autism spectrum disorders; and advocating for the needs of individuals with autism and their families.Autism Speaks was founded in February 2005 by Suzanne and Bob Wright, the grandparents of a child with autism. Mr. Wright is the former vice chairman of General Electric and chief executive officer of NBC and NBC Universal. Since its inception, Autism Speaks has committed over $180 million to research and developing innovative resources for families. Each year Walk Now for Autism Speaks events are held in more than 95 cities across North America. To learn more about Autism Speaks, please visit http://www.autismspeaks.org.

About Prometheus ResearchPrometheus Research provides data management services and web-native data-management software to biomedical researchers investigating autism and other neurodevelopmental disorders. Its team specializes in designing and building systems capable of accelerating complex interdisciplinary research and of multiplying the value of hard-won research data. Prometheus staff are consummate innovators, and Prometheus technology powers some of the most ambitious and important research endeavors in autism, including the Simons Foundation Autism Research Initiative (SFARI). Many of these innovations also are made available to the open source software community, most notably HTSQL, an instant Web interface for databases, and the Research Exchange Database, RexDB. To learn more about Prometheus Research, please visit http://www.prometheusresearch.com.

See the article here:
Autism Speaks Selects Prometheus Research to Develop Integrated Data Management System

Rethink Autism Wins Prestigious 2012 CODiE™ Award for Best Instructional Solution for Special Needs Students for …

NEW YORK, May 11, 2012 /PRNewswire/ --Rethink Autism, the first and only autism curriculum aligned with the Common Core State Standards, is an honored recipient of the 2012 SIIA CODiE Award for Best Instructional Solution for Special Needs Students, the second consecutive year it has won this award. The Software and Information Industry Association's (SIIA) CODiE Awards recognize excellence in digital content and educational technology.

"We recognize the tremendous challenges faced by families, school districts and organizations serving children on the autism spectrum. In developing the Rethink Autism platform, we wanted to make clinical best practices accessible, affordable and easy to use for anyone, anywhere in the world," said Daniel Etra, Co-founder and CEO. "With this award, and with thousands of users in schools, organizations, universities and homes in all 50 states, as well as 27 countries around the world, we really feel like we have achieved our goal."

Rethink Autism's unique web-based program provides parents and educators with a comprehensive evidence-based curriculum through 1,200+ video-based teaching steps, parent and staff training modules, an assessment tool, and progress tracking features. The curriculum, developed and endorsed by leaders in the field of autism treatment and research, spans the entire autism spectrum and covers a broad range of skills, including academics, language, social, motor, daily living, and behavior managements.

The CODiE Awards are the industry's only peer-reviewed awards program and provide member companies with a unique opportunity to earn praise from their competitors. From a wide range of nationally and internationally nominated products and services, third-party judges narrowed the field down to 128 finalists. From these finalists, SIIA members reviewed these finalists and voted to select 29 winners.

"This year's winners reflect excellence and vision," noted SIIA Vice President for the Education Division, Karen Billings. "I'm proud to congratulate them on the success of their applications, platforms, and products."

To learn more about Rethink Autism, visit the company's home page: http://www.rethinkautism.com/

To learn more about the SIIA CODiE Awards, visit the organization's home page: http://www.siia.net/codies/2012/

To learn more about the Common Core State Standards, visit the organization's home page: http://www.corestandards.org/

About Rethink Autism (http://www.rethinkautism.com)

Rethink Autism, Inc. seeks to ensure that every child on the autism spectrum has access to effective and affordable evidence-based treatment options by providing professionals, parents, and family members with the tools and information necessary to teach children with autism in a way that is easy to understand and apply. Rethink Autism was founded in 2007 and has its headquarters at 19 West 21st Street in New York City.

Read this article:
Rethink Autism Wins Prestigious 2012 CODiE™ Award for Best Instructional Solution for Special Needs Students for ...

How to be a Village for an Autism mom this Mother's Day

SIMI VALLEY, Calif., May 11, 2012 /PRNewswire/ -- Autism expert Lynette Louise of Brain and Body agrees that every mom deserves to be pampered and recognized on Mother's Day. For parenting partners and kids this is a great opportunity to prove that you appreciate the lengths mom goes to every day, by helping out for one! Unfortunately, moms of autism often get less pampered because families and friends aren't sure what to do.

Global autism expert, and more importantly, autism mom and individual Lynette Louise, would love to offer some simple suggestions!

Neighbors and Strangers: #1 Think 'Isn't that child beautiful!?' #2 Think 'Isn't that mom awesome!?' #3 Think 'How can I help?' #4 Don't think. Act! Open a door, push a cart, carry a bag, smile!

In-Laws and Extended Relatives: Hire a cleaning lady that uses all natural products and send her to clean-up the mess after Mother's Day.

Siblings: Engage in your special sib's favorite game of repetitive behavior for at least an hour, and laugh a lot!

Parenting Partner: Do ALL the child rearing for the day and then both of you go out to supper. (If the in-laws don't do their job, hire a maid to clean-up the mess. If you can't afford one, involve all the kids and do it yourselves.)

Best Friend: Take her and her special child out while the house gets cleaned.

MOM: Relax and trust your friends and family to do it all! You deserve a day!

Some of these tips and tricks (ie think wonderfully, smile and play favorite game with special sib) will make everyone feel more comfortable every day of the year. Surprisingly they also have the ability to help guide your children in skill acquisition and social comfort. Let Mother's Day be an excuse to begin making those simple, brain-changing adjustments! According to Lynette, "Sooner is better than later, though later is MUCH better than not at all."

Lynette Louise raised eight children four of them were on the spectrum of autism.She was able to guide all but one out of autism and into independence.Lynette travels internationally, performing and speaking on the subject of autism and the efficacy of neurofeedback (biofeedback for the brain).A doubly board-certified PhD candidate at UNM: College of Psychophysiology, she is the author of the inspirational and honest new book MIRACLES ARE MADE: A Real Life Guide to Autism and host of the WebTalk.net radio show A NEW SPIN ON AUTISM: ANSWERS!Her one-woman musical comedy show CRAZY TO SANE raises awareness -- and laughter --around the world.

Read more from the original source:
How to be a Village for an Autism mom this Mother's Day

How to be a Village for an Autism mom this Mother’s Day

SIMI VALLEY, Calif., May 11, 2012 /PRNewswire/ -- Autism expert Lynette Louise of Brain and Body agrees that every mom deserves to be pampered and recognized on Mother's Day. For parenting partners and kids this is a great opportunity to prove that you appreciate the lengths mom goes to every day, by helping out for one! Unfortunately, moms of autism often get less pampered because families and friends aren't sure what to do.

Global autism expert, and more importantly, autism mom and individual Lynette Louise, would love to offer some simple suggestions!

Neighbors and Strangers: #1 Think 'Isn't that child beautiful!?' #2 Think 'Isn't that mom awesome!?' #3 Think 'How can I help?' #4 Don't think. Act! Open a door, push a cart, carry a bag, smile!

In-Laws and Extended Relatives: Hire a cleaning lady that uses all natural products and send her to clean-up the mess after Mother's Day.

Siblings: Engage in your special sib's favorite game of repetitive behavior for at least an hour, and laugh a lot!

Parenting Partner: Do ALL the child rearing for the day and then both of you go out to supper. (If the in-laws don't do their job, hire a maid to clean-up the mess. If you can't afford one, involve all the kids and do it yourselves.)

Best Friend: Take her and her special child out while the house gets cleaned.

MOM: Relax and trust your friends and family to do it all! You deserve a day!

Some of these tips and tricks (ie think wonderfully, smile and play favorite game with special sib) will make everyone feel more comfortable every day of the year. Surprisingly they also have the ability to help guide your children in skill acquisition and social comfort. Let Mother's Day be an excuse to begin making those simple, brain-changing adjustments! According to Lynette, "Sooner is better than later, though later is MUCH better than not at all."

Lynette Louise raised eight children four of them were on the spectrum of autism.She was able to guide all but one out of autism and into independence.Lynette travels internationally, performing and speaking on the subject of autism and the efficacy of neurofeedback (biofeedback for the brain).A doubly board-certified PhD candidate at UNM: College of Psychophysiology, she is the author of the inspirational and honest new book MIRACLES ARE MADE: A Real Life Guide to Autism and host of the WebTalk.net radio show A NEW SPIN ON AUTISM: ANSWERS!Her one-woman musical comedy show CRAZY TO SANE raises awareness -- and laughter --around the world.

Read more from the original source:
How to be a Village for an Autism mom this Mother's Day

Study Identifies Cell Subtypes For Potential Personalized Cellular Therapies

Connie K. Ho for RedOrbit.com

A new study by researchers at the University of California, Los Angeles (UCLA) has discovered two adult stem cell-like subpopulations in adult human skin.

The findings allow for further research to be done in the area of personalized medicine and patient-specific cellular therapies.

The study, using technology from Fibrocell Science, allowed the researchers to identify and confirm two types of cells in human skin cell cultures; the possible source of stem cell-like subpopulations from skin biopsies would be faster to perform, painless, and less invasive than current extractions from adipose tissues and bone marrow.

The research, featured in the inaugural issue of BioResearch Open Access, discusses two subtypes of cells. BioResearch Open Access is a bimonthly, peer-reviewed journal. It features scientific topics like biochemistry, bioengineering, gene therapy, genetics, microbiology, neuroscience, regenerative medicine, stem cells, systems biology, tissue engineering and biomaterials, and virology.

Being able to identify two sub-populations of rare, viable and functional cells that behave like stem cells from within the skin is an important finding because both cell types have the potential to be investigated for diverse clinical applications, commented Dr. James A. Bryne, lead author of the report.

Brynes research, first at Stanford University then at UCLA, focused on reprogramming beginnings of cells from animals and then humans. A graduate of Cambridge University, Bryne studied the intra- and inter-species of epigenetic reprogramming. His work also highlighted how primate embryonic stem cells could be derived from somatic cell nuclear transfers.

The study published in BioResearch Open Access confirmed previous research that identified a rare population of cells in adult human skin that had a marker called stage-specific embryonic antigen 3 (SSEA3). Bryne and his colleagues found that there was an increase in the amount of SSEA3 expressing cells after injury to the human skin. It showed that the SSEA3 biomarker could be used to help identify and isolate cells with tissue-regenerative traits.

Finding these rare adult stem cell-like subpopulations in human skin is an exciting discovery and provides the first step towards purifying and expanding these cells to clinically relevant numbers for application to a variety of potential personalized cellular therapies for osteoarthritis, bone loss, injury and/or damage to human skin as well as many other diseases, remarked Bryne, an Assistant Professor of Molecular and Medical Pharmacology at the Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research at UCLA.

Bryne and his team used Fibrocell technology to collect cells from skin samples, cultured the cells in the lab, and purified them by fluorescence-activated cell sorting (FACS). The FACS tagged suspended cells with fluorescent markers for undifferentiated stem cells. The researchers were able to separate the rare cell subpopulations from other kinds of cells.

Link:
Study Identifies Cell Subtypes For Potential Personalized Cellular Therapies

Harvard Stem Cell Institute Sees Growth

At its founding eight years ago, the Harvard Stem Cell Institute had fewer than ten principal faculty members, according to Benjamin D. Humphreys, co-director of the HSCI Kidney Program. Today, that number has ballooned to more than 80.

In the past decade, Harvard has increasingly poured resources into groundbreaking research in one of the largest collections of stem cell research labs in the country.

According to HSCI co-director Douglas A. Melton, a professor in the stem cell and regenerative biology department, there are more than 800 Harvard affiliates in stem cell science scattered throughout roughly 80 laboratories. The largest concentration of stem cell researchers are located in Harvards Sherman Fairchild Building, which reopened in August of 2011 after it underwent a two-year demolition and reconstruction project to accommodate the stem cell and regenerative biology department.

In the past decade, Harvard has focused on centralizing this research with the creation of HSCI and the stem cell and regenerative biology department.

HSCI consists of scientists and practitioners interested in stem cell research from all over the Harvard community, including the Faculty of Arts and Sciences, the medical school, and 11 teaching hospitals and research institutions including the Childrens Hospital Boston and the Massachusetts General Hospital.

So far, HSCI has given out more than $100 million to its researchers, according to Humphreys.

"[Harvard has] definitely made a tangible commitment to stem cell research," Humphreys said. "The results are that we are leaders in certain areascertainly I can speak of the kidneynot even just in the U.S., but worldwide in terms of stem cell research in the kidney."

With important potential applications such as the generation of cells and tissues that could be used for cell-based therapies, stem cells are at the forefront of scientific research. Stem cells, which can differentiate into specific cell types, offer the possibility of a renewable source of replacement cells and tissues to treat some of the most serious diseases.

"What were doing at the HSCI Kidney Group is working collaboratively to identify new therapeutic strategies that will help slow disease progression," said Humphreys.

Still, Humphreys added that much more research is necessary before scientists can use stem cells to their fullest potential.

More here:
Harvard Stem Cell Institute Sees Growth

International Stem Cell Corporation Announces New Stem Cell Manufacturing Technologies to Support its Therapeutic …

CARLSBAD, Calif.--(BUSINESS WIRE)--

International Stem Cell Corporation (OTCBB: ISCO.OB - News) http://www.internationalstemcell.com today announced that the Company has developed new technologies to commercialize the use of human parthenogenetic stem cells (hpSC) to treat human diseases. The methods announced today are capable of producing populations of stem cells and their therapeutically valuable derivatives not only to a higher level of purity but also at a cost that is approximately several times lower than previously reported techniques.

ISCOs research team has developed a new method to derive high-purity populations of neural stem cells (NSC) from hpSC and further differentiate them into dopaminergic neurons. This method is capable of generating sufficient quantities of neuronal cells for ISCOs pre-clinical and clinical studies and is highly efficient as it requires substantially less time and labor in addition to using fewer costly materials than traditional methods. ISCOs technologies make possible the creation of billions of neuronal cells necessary for conducting such studies from a small batch of stem cells.

ISCO has also announced today that it has developed a new high-throughput cell culture method for growing human parthenogenetic stem cells (hpSC) in large quantities. This new technique is easily scalable and can produce the quantities of cGMP grade hpSC necessary for commercial and therapeutic applications.

One of the most challenging issues in commercializing stem cell based treatments is creating high-purity populations of stem cell derivatives at a reasonable cost. I believe the new methods we have developed solve this important problem and help position us for future clinical studies, says Dr. Ruslan Semechkin, Vice President, R&D.

About International Stem Cell Corporation

International Stem Cell Corporation is focused on the therapeutic applications of human parthenogenetic stem cells (hpSCs) and the development and commercialization of cell-based research and cosmetic products. ISCO's core technology, parthenogenesis, results in the creation of pluripotent human stem cells from unfertilized oocytes (eggs). hpSCs avoid ethical issues associated with the use or destruction of viable human embryos. ISCO scientists have created the first parthenogenic, homozygous stem cell line that can be a source of therapeutic cells for hundreds of millions of individuals of differing genders, ages and racial background with minimal immune rejection after transplantation. hpSCs offer the potential to create the first true stem cell bank, UniStemCell. ISCO also produces and markets specialized cells and growth media for therapeutic research worldwide through its subsidiary Lifeline Cell Technology, and stem cell-based skin care products through its subsidiary Lifeline Skin Care (www.lifelineskincare.com). More information is available at http://www.internationalstemcell.com or follow us on Twitter @intlstemcell.

To receive ongoing corporate communications, please click on the following link: http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0.

Forward-looking Statements

Statements pertaining to anticipated developments, the potential benefits of research programs and new manufacturing technologies, and other opportunities for the company and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to statements that contain words such as "will," "believes," "plans," "anticipates," "expects," "estimates,") should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products and technologies regulatory approvals, need and ability to obtain future capital, application of capital resources among competing uses, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the company's business, particularly those mentioned in the cautionary statements found in the company's Securities and Exchange Commission filings. The company disclaims any intent or obligation to update forward-looking statements.

Read more from the original source:
International Stem Cell Corporation Announces New Stem Cell Manufacturing Technologies to Support its Therapeutic ...

DiaGenic ASA: DiaGenic Reports Completion of Data Collection and Genetic Analyses in a Unique Study on Familial …

OSLO, Norway--(BUSINESS WIRE)--Regulatory News:

DiaGenic ASA (OSE:DIAG): DiaGenic today reports on the finalization of data collection and database lock of a blinded study in a Norwegian cohort of 80 patients with familial Parkinsons disease (PD). The majority of these patients are carrying a mutation in the parkin 8 gene (also called LRRK2) that significantly increases the risk of developing PD. Patients recruited from St Olavs University Hospital under the lead of Principal Investigator Professor Jan Aasly are all LRRK2 mutation carriers with or without the disease or healthy relatives. Unblinding of the study is set to the May 16th and analysis and reporting is expected to be completed during summer 2012.

As part of the overarching program on development of diagnostic biomarkers for PD, the objective of the study is to identify a biomarker for individuals at risk of developing the disease using material from LRRK2 individuals and relatives. The LRRK2 study is unique being the first blood based RNA analysis in pre symptomatic PD. The study is also expected to allow independent validation of DiaGenics European multicentre study that previously this year reported a high accuracy (88%) in PD patients reported February 8th 2012.

The collection of data from the Norwegian individuals with this rare mutation has been ongoing at St. Olav`s University Hospital in Trondheim, Norway, since 2009 and includes collection of blood for gene signature analysis, clinical variables and imaging of the brain. By taking blood samples from individuals with LRRK2 mutations and identifying a gene signature before signs of the disease occur, a general blood based diagnostic test for early PD can be developed.

The gene analyses of 96 samples including technical controls and samples of 82 participants from families with a LRRK2 gene mutation are performed on an Illumina whole genome platform and aims to identify disease related gene probes (i.e. gene transcripts) for disease specific diagnostic models. The gene analyses were completed May 7th and the study now enters into the phase of final bioinformatical analysis.

Professor Jan Aasly, Dept Neurology, St Olavs University Hospital, Trondheim, Norway comments: This unique study represents an opportunity to make new scientific discoveries in Parkinson`s Disease. Should we be able to identify a gene signature that is present before the onset of neurological signs in PD, in this form of familial PD, then we may be one step closer to identifying a diagnostic test for pre symptomatic PD.

DiaGenic CEO Dr Henrik Lund said: We are very pleased collaborate with St. Olavs University Hospital and Professor Aasly. We are especially grateful to the families that are committed to support scientific advancements in PD. With their support we are in a good position to start identifying novel biomarkers that in DiaGenics product development programs can mature into diagnostic tools to support early diagnosis and development of new drugs to treat PD. DiaGenic is committed to develop novel diagnostic tools for severe disorders, especially in PD and Alzheimers disease.

About PD

Parkinsons disease (PD) is the second most common neurodegenerative disorder after Alzheimers disease with more than 5 million patients worldwide, whereas 1 million are in the US. PD is a disorder of the central nervous system that results from the loss of cells in various parts of the brain. No cure is yet available, but several pharmaceutical companies are currently developing medicines many of which target disease modification in PD. There is no objective test for Parkinson's, so the rate of misdiagnosis can be relatively high, especially when the diagnosis is made by a non-specialist at an early stage of the disease.

PD research in DiaGenic

Read more from the original source:
DiaGenic ASA: DiaGenic Reports Completion of Data Collection and Genetic Analyses in a Unique Study on Familial ...

Distraught Parkinson's sufferer killed herself when driving licence was revoked

Horse lover had become depressed after condition meant she could no longer ride Inquest told she could not accept that the things she liked were becoming more and more difficult Losing driving licence was the 'final straw'

By Phil Vinter

PUBLISHED: 15:23 EST, 7 May 2012 | UPDATED: 15:28 EST, 7 May 2012

A mum committed suicide on the day her driving licence was revoked because Parkinson's Disease symptoms had become too bad.

Karen Bottrill, 51, hung herself following the DVLA (the vehicle licencing agancy) at a spot where her beloved daughter used to play as a child.

An inquest heard that Mrs Bottrill had requested space after leaving her home at Larkhill, in Salisbury Plain, Wiltshire, following the news.

Crushing news: Salisbury Coroner's Court heard that Karen Bottrill hung herself after the DVLA deemed her unable to drive a car because of her debilitating Parkinson's symptoms

Yesterday her husband Gordon, 50, said the DVLAs decision to ban her from driving was the final straw for his wife, after losing the ability to continue her passion for riding horses.

Mr Bottrill said Karen - who was first diagnosed with the debilitating nerve condition in 2006 - could not accept that all of the things she liked were becoming more and more difficult.

See more here:
Distraught Parkinson's sufferer killed herself when driving licence was revoked

Distraught Parkinson’s sufferer killed herself when driving licence was revoked

Horse lover had become depressed after condition meant she could no longer ride Inquest told she could not accept that the things she liked were becoming more and more difficult Losing driving licence was the 'final straw'

By Phil Vinter

PUBLISHED: 15:23 EST, 7 May 2012 | UPDATED: 15:28 EST, 7 May 2012

A mum committed suicide on the day her driving licence was revoked because Parkinson's Disease symptoms had become too bad.

Karen Bottrill, 51, hung herself following the DVLA (the vehicle licencing agancy) at a spot where her beloved daughter used to play as a child.

An inquest heard that Mrs Bottrill had requested space after leaving her home at Larkhill, in Salisbury Plain, Wiltshire, following the news.

Crushing news: Salisbury Coroner's Court heard that Karen Bottrill hung herself after the DVLA deemed her unable to drive a car because of her debilitating Parkinson's symptoms

Yesterday her husband Gordon, 50, said the DVLAs decision to ban her from driving was the final straw for his wife, after losing the ability to continue her passion for riding horses.

Mr Bottrill said Karen - who was first diagnosed with the debilitating nerve condition in 2006 - could not accept that all of the things she liked were becoming more and more difficult.

See more here:
Distraught Parkinson's sufferer killed herself when driving licence was revoked

Michael J. Fox Foundation Expands Funding to Envoy

JUPITER, Fla.--(BUSINESS WIRE)--

Envoy Therapeutics, Inc., a drug discovery company, today announced that it has been awarded a second grant from The Michael J. Fox Foundation (MJFF). The additional funding will enable the continued development of compounds that selectively act on the motor circuitry that is compromised in Parkinsons disease (PD) via modulation of a receptor target identified by Envoy. Further validation of the functional role of this biological target is intended to pave the way for the progression of compounds through preclinical development and eventually to improved treatment options for PD patients.

The objective of the MJFF-funded project is to develop an oral therapeutic that provides the symptomatic benefit of dopamine replacement therapy but with sustained efficacy and with minimal acute and long-term side effects. The therapeutic benefit of dopamine precursor L-DOPA (the current gold standard in treating PD) is hampered by serious side effects, including dyskinesia, compulsive behaviors and somnolence. Envoy Therapeutics bacTRAP technology enables the identification of new drug targets selectively expressed in brain circuits of therapeutic interest, thereby minimizing activity in circuits that may trigger unwanted side effects. Envoy has identified novel small molecule compounds that selectively engage the target of interest. Compounds have been optimized for potency, pharmacokinetic properties and central nervous system (CNS) penetration, and have shown efficacy in a PD model. With this funding, lead compounds will now be used to further validate the target hypothesis in more definitive in vivo models. Successful target validation will position the program to advance into safety assessment studies in readiness for clinical development.

Levodopa is still the standard of care for people with Parkinsons, but the side effects of levodopa treatment remain one of the most challenging aspects of living day to day with the disease. For this reason, developing improved symptomatic treatments that limit dyskinesia is a priority for our Foundation, said Todd Sherer, Ph.D., Chief Executive Officer of MJFF. We are hopeful that Envoys ongoing work to this end will lead to improved treatment for patients.

We are thrilled to expand our collaboration with the team at The Michael J. Fox Foundation, and to advance closer to safety studies and clinical development on a compound to effectively modulate the highly selective target we have discovered with our bacTRAP technology, added Steve Hitchcock, Ph.D., Senior Vice President of Drug Discovery at Envoy. Successful completion of this next phase will move us another significant step forward toward human clinical development.

About The Michael J. Fox Foundation for Parkinsons Research

As the worlds largest private funder of Parkinsons research, The Michael J. Fox Foundation is dedicated to accelerating a cure for Parkinsons disease and improved therapies for those living with the condition today. The Foundation pursues its goals through an aggressively funded, highly targeted research program coupled with active global engagement of scientists, Parkinsons patients, business leaders, clinical trial participants, donors and volunteers. In addition to funding over $289 million in research to date, the Foundation has fundamentally altered the trajectory of progress toward a cure. Operating at the hub of worldwide Parkinsons research, the Foundation forges groundbreaking collaborations with industry leaders, academic scientists and government research funders; increases Parkinsons awareness through high-profile advocacy, events and outreach; and coordinates the grassroots involvement of thousands of Team Fox members around the world.

For more information, visit: http://www.michaeljfox.org ; http://www.facebook.com/michaeljfoxfoundation

About Envoy Therapeutics

Envoy Therapeutics mission is to discover new drugs with superior efficacy and fewer side effects than existing treatments. The companys bacTRAP technology enables the identification of proteins in vivo that are produced by specific cell types without requiring the isolation of those cells. The technology is especially powerful in tissues of the brain, where many hundreds of cell types are intermingled. Because therapeutically modulating the activity of a specific cell type has until now been prevented by the inability to determine which proteins are uniquely expressed by that cell type, Envoy brings a new day in drug discovery.

Excerpt from:
Michael J. Fox Foundation Expands Funding to Envoy

Device ‘Programs’ Relief For Dighton Woman With Parkinson’s Disease

Jillian Courcy (Photo by Carl Stevens)

DIGHTON (CBS) -Jillian Courcy of Dighton had just given birth to her second son when she started experiencing hand tremors and slurred speech at the age of 34.

She had Parkinsons disease.

I was diagnosed in 2006, late 2006 into 2007, she told WBZ NewsRadio 1030.

All of sudden, Jillians world was turned upside down.

I couldnt make pancakes. I couldnt stand up. I was having a hard time thinking, these are the dreams I have, I should be able to make dinners for my family, mow the lawn, do different things around the house that I used to be able to do that I cant do so well as much any more, like gardening. I used to love being able to garden. But to grab things with my hands, the fine motor movements, its not easy for me to do those things any more, Courcy said.

WBZ NewsRadio 1030s Carl Stevens reports

But then, last month, at Rhode Island Hospital, she underwent surgery. Its a relatively new procedure called Deep Brain Stimulation, also known as DBS.

It has probes that go into it, like little conductors on it, that go into the back of the brain. They place these two little probes into your brain, she said.

The probes in the brain receive an electric stimulus from a device implanted in her neck, a device which Jillian controls with a small remote.

More:
Device ‘Programs’ Relief For Dighton Woman With Parkinson’s Disease

Amarantus BioSciences Issues First Annual CEO Letter to Shareholders

SUNNYVALE, Calif., May 7, 2012 /PRNewswire/ -- Amarantus BioSciences, Inc. (AMBS.OB), a biotechnology company developing the MANF Program for Parkinson's Disease and other brain disorders, today released a letter from President & CEO Gerald E. Commissiong to its shareholders:

OUR MISSION

Healing Patients For those among us who operate in this volatile, uncertain and challenging field of development-stage biotechnology, it is critical that healing patients always remains the top priority in each challenge we face. From the moment I took the helm as Chief Executive of Amarantus BioSciences, Inc. ("Amarantus", "Company", "we", or "us"), healing patients with Parkinson's disease has been front and center of my mission. In order to successfully translate the remarkable scientific advances our researchers and collaborators are making in the lab into F.D.A approved products improving lives throughout the world, we must also take into consideration another key stakeholder that supports the development and commercialization of new products in the healthcare system - the shareholder. Over the course of the last fifteen years, the many different companies that have brought revolutionary life-saving treatments to market for oncology patients worldwide, together, have definitively established that improvements in the understanding of molecular biology in the lab can lead to tremendous advances in treating deadly diseases in patients all the while leading to significant returns for shareholders. I believe the dawn of a similar era is now at hand in the development of new treatments for nervous-system disorders and at the forefront of this period are advances in molecular neuroscience centered on neurotrophic factors and astrocytes. Armed with our PhenoGuard astrocyte cell lines (which led to the discovery of the neurotrophic factor MANF), and our proprietary Parkinson's cell culture (which was crucial to Teva Pharmaceuticals' development of Rasagiline), we believe Amarantus is poised to bring forward exciting new treatments for Parkinson's centered on our flagship MANF Program. These treatments could improve the livelihood of millions of patients who suffer from brain disorders such as Parkinson's disease while hopefully returning significant value to Amarantus shareholders.

OUR HISTORY

Amarantus was founded to develop new treatments for brain-related conditions based on technology that was originally conceived at the US Government's National Institutes of Health. Shortly after our incorporation in January 2008, we acquired certain key intellectual property pioneered by our scientific founder enabling our flagship MANF Program to develop new experimental treatments for Parkinson's disease and other nervous-system disorders. Independent researchers in Europe, Asia and North America, as well as Company scientists and collaborators, have worked tirelessly towards validating this approach and characterizing the full potential of the MANF Program by translating it towards the development of new treatments for an increasing number of apoptosis-mediated disorders. Our strategy going forward will be to continue to build strong relationships with the key stakeholders within academia, not-for-profit organizations, governments, reimbursement agencies, and industry necessary to optimize our development programs for maximum impact on the global healthcare system.

GOING PUBLIC

In May of 2011, we transformed from an angel-funded private company into a publicly-traded company by way of a reverse merger. At that time, we believed becoming a public company would significantly advance our corporate development efforts by leveraging the liquidity provided by our new public equity to raise capital and advance our core programs, all the while allowing us to acquire complementary technologies to create additional product offerings around our MANF Program. Shortly after trading in our shares began in June of 2011, market conditions were adversely impacted by a crisis of U.S. Sovereign Debt that was precipitated by political gridlock in Congress and cemented by a downgrade of U.S. debt by the debt rating agency Standard & Poor's. In November of 2011, in response to market turmoil caused primarily by certain U.S.-listed Chinese companies fraudulently deceiving investors, the S.E.C. made the regulations for companies that had recently completed reverse mergers significantly more stringent, possibly creating a negative perception of 'reverse merger' companies. These events, which were completely outside of our control, made developing broad investor interest in an early-stage biotechnology company with limited trading history such as ours significantly more challenging than originally anticipated. Despite these challenges of the last year, we were able to raise sufficient capital to fund our core programs with a small group of investors who believed in our technology's potential. Going forward, we are hopeful to raise capital in more efficient ways from a broader group of investors and believe that the new regulations surrounding the crowdfunding portion of the J.O.B.S. bill recently signed into law could have a significant positive impact on our fundraising endeavors. In order to position ourselves to excel in this emergent fundraising environment for public companies, management of Amarantus intends to engage more directly with investors over the course of the next several months to increase awareness of our programs and gain broader acceptance of our business plan from the global investment community.

CORPORATE DEVELOPMENTS

On May 30, 2011, we entered into a letter agreements regarding Intellectual Properties Licensing and Collaboration Arrangements with Generex Biotechnology Corporation ("Generex", OTCBB: GNBT). Under the letter agreements, Generex will grant to us a non-exclusive worldwide license for the clinical and regulatory development and commercialization of our programs in combination with the Generex Technologies, excluding the field of diabetes treatment. We are continuing to work towards completing that transaction as we believe there is significant value in combining their RapidMist technology with our current and future pipeline. In January of this year, we entered into a licensing agreement with Power3 Medical Products, Inc. ("Power3", OTCBB: PWRM)) to acquire certain rights to a blood test capable of reliably diagnosing patients who have Parkinson's disease in order to develop a revenue generating product that would further enable our lead Parkinson's treatment program. On March 15, 2012, Power3 declared bankruptcy and we are currently working with the bankruptcy trustee to assess our rights and options relating to the license and the related intellectual property. Our intent is to acquire outright the assets relevant to our MANF Program and fund their further development. Most recently, on April 30th, 2012 we executed a letter of intent with Rainbow Biosciences ("Rainbow", OTCBB: RBCC) to provide funding towards one or more of our Parkinson's programs within 60 days. We are working with Rainbow to determine which program is most suitable for the contemplated funding and what the best structure of the collaboration would be for both parties. We will continue to inform the marketplace on the progress of these transactions and how they relate to the overall business of developing our MANF Program to deliver new treatments to patients.

MILESTONES

View original post here:
Amarantus BioSciences Issues First Annual CEO Letter to Shareholders